| Assess price negotiation risk | Assess mitigation strategies | |
|---|---|---|
| Step 1
Assess risk of drug being selected by CMS | Step 2
Anticipated negotiation outcome | Step 3
Other considerations |
| Exposure to price negotiations will have substantial impact on pricing and revenue potential
Indirect exposure, including competitors selected for negotiation, will also have significant impact | Companies need proactive strategies to defend an asset in negotiations to support optimal pricing This should be embedded in clinical development and continued throughout product lifecycle | Companies should consider a wider range of strategies, both product-specific and beyond, to limit the impact of price negotiations |
